Cost-effectiveness analysis (CEA) of adjuvant trastuzumab therapy use in HER2-positive early-stage breast cancer (EBC)

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Cost-Effectiveness Analysis of 1-Year Adjuvant Trastuzumab Therapy of Early-Stage Her2-Positive Breast Cancer

Value in Health ◽

10.1016/j.jval.2014.08.107 ◽

2014 ◽

Vol 17 (7) ◽

pp. A735 ◽

Cited By ~ 1

Author(s):

Nguyen TTC ◽

Nguyen TTT

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Stage ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Her2 Positive Breast Cancer ◽

Trastuzumab Therapy ◽

Effectiveness Analysis ◽

Positive Breast Cancer

Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma

PharmacoEconomics ◽

10.1007/s40273-016-0474-0 ◽

2016 ◽

Vol 35 (4) ◽

pp. 425-438 ◽

Cited By ~ 8

Author(s):

Kelly Fust ◽

Xiaoyan Li ◽

Michael Maschio ◽

Guillermo Villa ◽

Anju Parthan ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Febrile Neutropenia ◽

Hodgkin Lymphoma ◽

Early Stage ◽

Treatment Strategies ◽

Non Hodgkin Lymphoma ◽

Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada

Journal of Medical Economics ◽

10.3111/13696998.2014.979938 ◽

2014 ◽

Vol 18 (3) ◽

pp. 173-188 ◽

Cited By ~ 17

Author(s):

C. L. Attard ◽

A. N. Pepper ◽

S. T. Brown ◽

M. F. Thompson ◽

P.-O. Thuresson ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Locally Advanced ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Trastuzumab Therapy ◽

Effectiveness Analysis ◽

Positive Breast Cancer

Cost-Effectiveness Analysis of Intraoperative Radiation Therapy for Early-Stage Breast Cancer

Annals of Surgical Oncology ◽

10.1245/s10434-013-2997-3 ◽

2013 ◽

Vol 20 (9) ◽

pp. 2873-2880 ◽

Cited By ~ 41

Author(s):

Michael D. Alvarado ◽

Aron J. Mohan ◽

Laura J. Esserman ◽

Catherine C. Park ◽

Brittany L. Harrison ◽

...

Keyword(s):

Breast Cancer ◽

Radiation Therapy ◽

Cost Effectiveness ◽

Early Stage ◽

Intraoperative Radiation Therapy ◽

Intraoperative Radiation ◽

Economic evaluation of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer: systematic review and quality assessment

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1080/14737167.2020.1819795 ◽

2020 ◽

pp. 1-10 ◽

Cited By ~ 1

Author(s):

Anne Julienne Genuino ◽

Mac Ardy Junio Gloria ◽

Usa Chaikledkaew ◽

Thanyanan Reungwetwattana ◽

Ammarin Thakkinstian

Keyword(s):

Breast Cancer ◽

Systematic Review ◽

Economic Evaluation ◽

Quality Assessment ◽

Early Stage ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy

Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer

Journal of Managed Care & Specialty Pharmacy ◽

10.18553/jmcp.2020.26.2.221 ◽

2020 ◽

Vol 26 (2) ◽

pp. 221-221

Author(s):

Phuong T. Tran ◽

Vakaramoko Diaby

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Stage ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Effectiveness Analysis ◽

Positive Breast Cancer

Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen alone or in combination) trial

British Journal of Cancer ◽

10.1038/sj.bjc.6603804 ◽

2007 ◽

Vol 97 (2) ◽

pp. 152-161 ◽

Cited By ~ 38

Author(s):

R Mansel ◽

◽

G Locker ◽

L Fallowfield ◽

Á Benedict ◽

...

Keyword(s):

Breast Cancer ◽

United Kingdom ◽

Cost Effectiveness ◽

Adjuvant Therapy ◽

Early Stage ◽

The United Kingdom ◽

Effectiveness Analysis ◽

Treatment Analysis

PCN20 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB FOR TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER IN THE SAUDI ARABIAN SETTING

Value in Health ◽

10.1016/s1098-3015(10)66557-6 ◽

2008 ◽

Vol 11 (6) ◽

pp. A465-A466

Author(s):

H AlOmar ◽

AS Zazaa ◽

M AlFayyadh ◽

JA Ray

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

Saudi Arabian ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Response to: ‘Reply to: Who Should Bear the Cost of Convenience? A Cost-effectiveness Analysis Comparing External Beam and Brachytherapy Radiotherapy Techniques for Early Stage Breast Cancer’

Clinical Oncology ◽

10.1016/j.clon.2017.03.013 ◽

2017 ◽

Vol 29 (6) ◽

pp. 393-394

Author(s):

M. McGuffin ◽

T. Merino ◽

B. Keller ◽

J.-P. Pignol

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Stage ◽

External Beam ◽

Effectiveness Analysis ◽

Radiotherapy Techniques ◽

The Cost

Who Should Bear the Cost of Convenience? A Cost-effectiveness Analysis Comparing External Beam and Brachytherapy Radiotherapy Techniques for Early Stage Breast Cancer

Clinical Oncology ◽

10.1016/j.clon.2016.11.010 ◽

2017 ◽

Vol 29 (3) ◽

pp. e57-e63 ◽

Cited By ~ 11

Author(s):

M. McGuffin ◽

T. Merino ◽

B. Keller ◽

J.-P. Pignol

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Stage ◽

External Beam ◽

Effectiveness Analysis ◽

Radiotherapy Techniques ◽

The Cost